Objective To evaluate the influence of prior use of carbamazepine (CBZ) and other
antiepileptic drugs (AED s) with a putatively similar mechanism of action (inhibition of …

Purpose To assess the efficacy, safety and tolerability of eslicarbazepine acetate (ESL) in
patients transitioning from carbamazepine or oxcarbazepine to ESL in clinical practice, by …

Objective To assess the efficacy and safety of eslicarbazepine acetate (ESL) as
monotherapy in North American patients with partial‐onset seizures (POS). Methods This …

Objective We assessed the efficacy and safety of once‐daily eslicarbazepine acetate in
comparison with twice‐daily (BID) controlled‐release carbamazepine (carbamazepine‐CR) …

Objective: To assess the efficacy and safety of eslicarbazepine acetate (ESL) monotherapy.
Methods: This post hoc pooled analysis of 2 randomized double-blind studies (093-045 and …

OBJECTIVE: Investigate the safety of eslicarbazepine acetate (ESL) as adjunctive therapy
for partial-onset seizures (POS) with/without concomitant carbamazepine (CBZ) …

OBJECTIVE: Investigate the efficacy of eslicarbazepine acetate (ESL) as adjunctive therapy
for partial-onset seizures (POS) with/without concomitant carbamazepine (CBZ) …

Abstract Background Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD)
anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is …

Objective To investigate whether adjunctive eslicarbazepine acetate (ESL) could lead to
exacerbation of seizures in some patients. Methods Post‐hoc analysis of data pooled from …

Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed as
adjunctive therapy in adults with partial-onset or focal seizures. Objective To evaluate in a …